Everyday Living® Your information source for products, shopping, marketing and business services, health matters, home and garden, food and lesiure, weight loss, anti-ageing surgical procedures and non-surgical rejuvenation treatments. www.everydayliving.com®
Monday, February 3, 2025
Thursday, January 30, 2025
Monday, January 27, 2025
Thursday, January 23, 2025
Tuesday, January 21, 2025
Apple Fritters with Vanilla Sugar
These apple fritters are a sweet end to a Rosh Hashanah feast, while offering a glimpse into Roman Jewish cuisine.
https://www.saveur.com/recipes/apple-fritters-with-vanilla-sugar/?utm_campaign=trueanthem&utm_medium=social&utm_source=facebook&fbclid=IwAR0NFjDKOH2kZD_VaXID8Fsqqmhli_zgeb493BL27jVzL9X2o99DHDAdyxMThursday, January 16, 2025
Saturday, January 11, 2025
Wednesday, January 8, 2025
Subscribe to:
Posts (Atom)
A systematic review of 26 randomized controlled trials (RCTs) finds that among glucagon-like peptide 1 (GLP-1) receptor agonists and co-agonists on the market or still being investigated, the experimental drug retatrutide (Eli Lilly and Company) produces the greatest weight loss.
The review, conducted by researchers at McGill University, Montreal, Quebec, Canada, examined three commercially available medications in the class and nine that have not yet received regulatory approval.
In healthy adults with overweight or obesity who did not have diabetes, the highest mean reductions in relative and absolute body weight were achieved with once-weekly triple glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 and glucagon receptor agonist retatrutide, followed by the dual GIP/GLP-1 agonist tirzepatide (Eli Lilly and Company) and lastly by the GLP-1 agonist semaglutide (Novo Nordisk), according to the authors.